Sitting around the house, sneezing, coughing, wheezing, and knowing a trip to the doctor will result in being told 'you have a cold'  could be a thing of the past soon.

Australian drug maker Biota has released results of testing with it's new drug Vapendavir reportedly shows the drug greatly shortened the duration and severity of the rhinovirus,  the one that causes what is known as "the common cold."   Rhinovirus is the most often diagnosed source for colds in humans.

Clinical tests on 300 people showed it reduced the effects of the "cold" in approxmiately 1.7 days.  Doctors say it now must be tested on a larger scale, and before it will be approved and marketed, it must show it can fill an unmet need in healthcare.   Doctors say if it reduces the length and severity of colds-especially for those with asthma, then it would be an important medical breakthrough.